caffeine has been researched along with Porphyria Cutanea Tarda in 1 studies
Porphyria Cutanea Tarda: An autosomal dominant or acquired porphyria due to a deficiency of UROPORPHYRINOGEN DECARBOXYLASE in the LIVER. It is characterized by photosensitivity and cutaneous lesions with little or no neurologic symptoms. Type I is the acquired form and is strongly associated with liver diseases and hepatic toxicities caused by alcohol or estrogenic steroids. Type II is the familial form.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bulaj, ZJ | 1 |
| Franklin, MR | 1 |
| Phillips, JD | 1 |
| Miller, KL | 1 |
| Bergonia, HA | 1 |
| Ajioka, RS | 1 |
| Griffen, LM | 1 |
| Guinee, DJ | 1 |
| Edwards, CQ | 1 |
| Kushner, JP | 1 |
1 other study available for caffeine and Porphyria Cutanea Tarda
| Article | Year |
|---|---|
Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda.
Topics: Administration, Cutaneous; Adult; Caffeine; Case-Control Studies; Cytochrome P-450 CYP1A2; Estrogen | 2000 |